HIV drug resistance testing now accessible to resource-limited settings

A major goal of the United Nations’ effort to address the world AIDS epidemic is the UNAIDS 90-90-90 target: by the year 2020, 90% of all people living with HIV will know their HIV status; 90% of all people with a diagnosed HIV infection will receive sustained antiretroviral therapy; and 90% of all people receiving antiretroviral therapy will have viral suppression.

This 90-90-90 target is helping to drive improved access to antiretroviral drugs (ARVs) in resource-limited settings, and thus the need for more widespread drug resistance testing. The US Centers for Disease Control and Prevention (CDC) previously developed a low-cost and broadly sensitive assay for HIV drug resistance that is currently used in 20 CDC and World Health Organization labs in Africa and Asia. In collaboration with the CDC, Thermo Fisher Scientific has further developed the assay.

The HIV-1 Genotyping Kit helps to address needs in resource-limited settings

  • Cost-effective assay
  • Scalable workflow
  • Easy-to-read sequencing results
  • Free software for assembly and interpretation
  • Benefits of standardization, compared to in-house validated lab-developed tests

The Applied Biosystems™ HIV-1 Genotyping Kit harnesses gold-standard Sanger sequencing technology to amplify and reliably sequence the diverse and rapidly evolving HIV-1 virus. The kit enables reliable genotyping of the genetically diverse HIV-1 virus from plasma and dried blood spot (DBS) samples, to detect resistance to protease inhibitors, nucleoside reverse-transcriptase inhibitors, and non-nucleoside reverse-transcriptase inhibitors.

Better subtype inclusivity

  • Detects HIV-1 subtypes A, B, C, D, AE, CRF01_AE, CRF02_AG, and AG
  • Detects mutations in the protease and reverse transcriptase regions of the HIV-1 pol gene
  • Generate genotyping results for plasma and dried blood spot samples, with a limit of detection (LOD) of 1,000 copies/mL and 2,000 copies/mL, respectively

A trusted assay developed and manufactured by a trusted partner

  • Improved Applied Biosystems™ assay workflow, developed by Thermo Fisher Scientific in collaboration with the CDC
  • Total workflow for processing 14 samples is ~14 hr from extracted viral RNA to results, with total hands-on time of less than 3 hr


The HIV-1 Genotyping Kit offers robust test performance

Sensitivity (LOD)

1,000 copies/mL (plasma sample)
2,000 copies/mL (DBS sample*)

Low detection limit

Plasma sample: 99.6%
DBS sample: 99.6%

1,000 copies/mL (plasma sample)

HIV-1 subtypes A, B, C, D, CRF01_AE,
and CRF02_AG

2,000 copies/mL (DBS sample*)

Plasma sample: 98.1%
DBS sample: 98.4%

*DBS samples must be processed within 2 weeks of collection under ambient storage conditions.


Assay workflow


Ordering information